WO2006065827A3 - Cell lines for production of replication-defective adenovirus - Google Patents
Cell lines for production of replication-defective adenovirus Download PDFInfo
- Publication number
- WO2006065827A3 WO2006065827A3 PCT/US2005/045097 US2005045097W WO2006065827A3 WO 2006065827 A3 WO2006065827 A3 WO 2006065827A3 US 2005045097 W US2005045097 W US 2005045097W WO 2006065827 A3 WO2006065827 A3 WO 2006065827A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell lines
- production
- complement
- replication
- defective adenovirus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05853909A EP1831352B1 (en) | 2004-12-13 | 2005-12-12 | Cell lines for production of replication-defective adenovirus |
CA2590943A CA2590943C (en) | 2004-12-13 | 2005-12-12 | Cell lines for production of replication-defective adenovirus |
MX2007007145A MX2007007145A (en) | 2004-12-13 | 2005-12-12 | Cell lines for production of replication-defective adenovirus. |
AT05853909T ATE516343T1 (en) | 2004-12-13 | 2005-12-12 | CELL LINES FOR PRODUCING REPLICATION DEFECTIVE ADENOVIRUS |
CN2005800480722A CN101208425B (en) | 2004-12-13 | 2005-12-12 | Cell lines for production of replication-defective adenovirus |
JP2007545722A JP4621743B2 (en) | 2004-12-13 | 2005-12-12 | Cell lines for the production of replication-deficient adenoviruses. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63556104P | 2004-12-13 | 2004-12-13 | |
US60/635,561 | 2004-12-13 | ||
US67448805P | 2005-04-25 | 2005-04-25 | |
US60/674,488 | 2005-04-25 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006065827A2 WO2006065827A2 (en) | 2006-06-22 |
WO2006065827A9 WO2006065827A9 (en) | 2006-08-24 |
WO2006065827A3 true WO2006065827A3 (en) | 2006-10-12 |
Family
ID=36282846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/045097 WO2006065827A2 (en) | 2004-12-13 | 2005-12-12 | Cell lines for production of replication-defective adenovirus |
Country Status (8)
Country | Link |
---|---|
US (1) | US7851218B2 (en) |
EP (1) | EP1831352B1 (en) |
JP (2) | JP4621743B2 (en) |
CN (1) | CN101208425B (en) |
AT (1) | ATE516343T1 (en) |
CA (1) | CA2590943C (en) |
MX (1) | MX2007007145A (en) |
WO (1) | WO2006065827A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1655827B (en) | 2002-05-27 | 2010-06-23 | 佩尔·松内·霍尔姆 | Novel use of adenoviruses and nucleic acids coding therefor |
US20070110719A1 (en) | 2003-11-14 | 2007-05-17 | Holm Per S | Novel use of adenoviruses and nucleic acids that code for said viruses |
EP1831352B1 (en) | 2004-12-13 | 2011-07-13 | CANJI, Inc. | Cell lines for production of replication-defective adenovirus |
US20090232800A1 (en) * | 2004-12-31 | 2009-09-17 | Per Sonne Holm | E1-minus adenoviruses and use thereof |
JP5097714B2 (en) * | 2005-12-12 | 2012-12-12 | カンジ,インコーポレイテッド | Adenovirus expression vector with expression cassette in E1 region and inactivated E2B polymerase |
WO2011046757A2 (en) * | 2009-10-12 | 2011-04-21 | Rajabrata Sarkar | Accelerating thrombus resolution through augmentation of p53 activity |
EP2764012B1 (en) | 2011-10-05 | 2022-02-23 | GenVec, Inc. | Adenoviral vectors and methods of use |
CN107574154A (en) | 2011-10-05 | 2018-01-12 | 金维克有限公司 | Monkey (gorilla) adenovirus or adenovirus vector and its application method |
BR112014008249B1 (en) | 2011-10-05 | 2022-03-15 | Genvec Inc | Adenovirus or adenoviral vector and composition with the same |
KR101427200B1 (en) * | 2011-11-24 | 2014-08-07 | 주식회사 바이로메드 | A Novel Cell Line for Producing Adenovirus and Its Uses |
US9676824B2 (en) | 2012-05-29 | 2017-06-13 | Genvec, Inc. | Herpes simplex virus vaccine |
EP2986306A4 (en) | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | Methods of using interleukin-10 for treating diseases and disorders |
EP3341012A4 (en) | 2015-08-25 | 2019-03-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CN110832072B (en) * | 2017-04-21 | 2023-11-07 | 真基因太科公司 | Cell line for producing non-replicating adenovirus and method for preparing said cell line |
CN111032209A (en) * | 2017-07-10 | 2020-04-17 | 简·探针公司 | Analysis system and method |
CA3120715A1 (en) | 2018-11-21 | 2020-05-28 | Mayo Foundation For Medical Education And Research | Adenoviruses and methods for using adenoviruses |
CA3174985A1 (en) * | 2020-04-07 | 2021-10-14 | Lung Biotechnology Pbc | Adenoviral expression vector and methods and cell lines for production |
CN113736780A (en) * | 2020-05-28 | 2021-12-03 | 暨南大学 | BCBL1 cell line with p300 gene knockout function as well as construction method and application thereof |
CN112156181A (en) * | 2020-09-29 | 2021-01-01 | 广州恩宝生物医药科技有限公司 | Adenovirus quadrivalent vaccine |
CN117264902A (en) * | 2022-06-15 | 2023-12-22 | 上海元宋生物技术有限公司 | Construction method and application of adenovirus packaging and production cell line |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6835557B1 (en) * | 1980-01-08 | 2004-12-28 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides |
US6210939B1 (en) * | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
TW442569B (en) * | 1993-10-25 | 2001-06-23 | Canji Inc | Recombinant adenoviral vector |
US5837520A (en) * | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
DE69633565T3 (en) * | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRES, FOR USE IN GENE THERAPY |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US20050025742A1 (en) | 1996-01-08 | 2005-02-03 | Canji, Inc. | Methods and compositions for interferon therapy |
CA2177085C (en) * | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
US6248514B1 (en) * | 1996-07-09 | 2001-06-19 | Canji, Inc. | Methods for measuring viral infectivity |
US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
US6146891A (en) * | 1997-01-31 | 2000-11-14 | Schering Corporation | Methods for cultivating cells and propagating viruses |
CN100374551C (en) | 1998-02-17 | 2008-03-12 | 先灵公司 | Compositions comprising viruses and methods for concentrating virus preparations |
US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5994134A (en) * | 1998-05-04 | 1999-11-30 | Canji, Inc. | Viral production process |
US6649158B1 (en) * | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
US7001770B1 (en) * | 1998-10-15 | 2006-02-21 | Canji, Inc. | Calpain inhibitors and their applications |
US6430595B1 (en) * | 1999-05-20 | 2002-08-06 | Cisco Technology, Inc. | Method and apparatus for establishing a database used for correlating information gathered via SNMP |
US20020064860A1 (en) * | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
US7026164B2 (en) * | 2003-07-03 | 2006-04-11 | Cell Genesys, Inc. | Adenovirus packaging cell lines |
EP1691844B1 (en) | 2003-12-10 | 2011-03-23 | CANJI, Inc. | Methods and compositions for treatment of interferon-resistant tumors |
EP1831352B1 (en) | 2004-12-13 | 2011-07-13 | CANJI, Inc. | Cell lines for production of replication-defective adenovirus |
US20090053759A1 (en) | 2006-02-10 | 2009-02-26 | Freie Universitat Berlin | Method and device for preparing biological samples |
-
2005
- 2005-12-12 EP EP05853909A patent/EP1831352B1/en active Active
- 2005-12-12 CN CN2005800480722A patent/CN101208425B/en not_active Expired - Fee Related
- 2005-12-12 JP JP2007545722A patent/JP4621743B2/en not_active Expired - Fee Related
- 2005-12-12 AT AT05853909T patent/ATE516343T1/en not_active IP Right Cessation
- 2005-12-12 US US11/301,309 patent/US7851218B2/en active Active
- 2005-12-12 MX MX2007007145A patent/MX2007007145A/en unknown
- 2005-12-12 CA CA2590943A patent/CA2590943C/en not_active Expired - Fee Related
- 2005-12-12 WO PCT/US2005/045097 patent/WO2006065827A2/en active Application Filing
-
2010
- 2010-09-06 JP JP2010199416A patent/JP2011015696A/en not_active Withdrawn
Non-Patent Citations (4)
Title |
---|
DORONIN K ET AL: "Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 13, July 2000 (2000-07-01), pages 6147 - 6155, XP002162706, ISSN: 0022-538X * |
HOWE ET AL: "Matching complementing functions of transformed cells with stable expression of selected viral genes for production of E1-deleted adenovirus vectors", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 345, no. 1, 5 February 2006 (2006-02-05), pages 220 - 230, XP005252864, ISSN: 0042-6822 * |
HOWE J A ET AL: "Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY. NOV 2000, vol. 2, no. 5, November 2000 (2000-11-01), pages 485 - 495, XP002381689, ISSN: 1525-0016 * |
HOWE J A ET AL: "Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 87, August 1990 (1990-08-01), pages 5883 - 5887, XP002134798, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
JP4621743B2 (en) | 2011-01-26 |
JP2011015696A (en) | 2011-01-27 |
US20060270041A1 (en) | 2006-11-30 |
JP2008522630A (en) | 2008-07-03 |
CA2590943C (en) | 2013-10-22 |
EP1831352B1 (en) | 2011-07-13 |
CA2590943A1 (en) | 2006-06-22 |
CN101208425A (en) | 2008-06-25 |
US7851218B2 (en) | 2010-12-14 |
ATE516343T1 (en) | 2011-07-15 |
CN101208425B (en) | 2011-01-26 |
WO2006065827A2 (en) | 2006-06-22 |
MX2007007145A (en) | 2007-08-20 |
WO2006065827A9 (en) | 2006-08-24 |
EP1831352A2 (en) | 2007-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006065827A3 (en) | Cell lines for production of replication-defective adenovirus | |
WO2001023597A3 (en) | Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus | |
WO2007070392A3 (en) | Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase | |
Imler et al. | Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. | |
WO2004001032A3 (en) | Stable adenoviral vectors and methods for propagation thereof | |
WO2005001103A3 (en) | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses | |
AU5152998A (en) | Improved adenovirus vectors | |
NZ594355A (en) | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof | |
CA2177085A1 (en) | Adenovirus e1-complementing cell lines | |
WO1998039466A3 (en) | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof | |
WO2001058940A3 (en) | Adenoviral capsid containing chimeric protein IX | |
WO2001036650A3 (en) | An oncolytic adenovirus | |
WO1998039464A3 (en) | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same | |
DE69425989D1 (en) | New complementation cell lines for defective adenoviral vectors | |
WO2006127956A3 (en) | Rapid production of adenovirus-free recombinant adenovirus vectors | |
WO1998039467A3 (en) | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof | |
AU2001294624A1 (en) | Recombinant adenovirus vectors that are replication-competent in tert-expressing cells | |
Marcellus et al. | Expression of p53 in Saos-2 osteosarcoma cells induces apoptosis which can be inhibited by Bcl-2 or the adenovirus E1B-55 kDa protein. | |
WO2008095027A3 (en) | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene | |
WO2004099422A3 (en) | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes | |
CA2448908A1 (en) | Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization | |
WO2005060515A3 (en) | An oncolytic adenovirus | |
PL376573A1 (en) | Adenovirus expressing genes in reverse order and use thereof | |
WO2008067025A3 (en) | Oncolytic adenoviruses and uses thereof | |
JP2007507216A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200580048072.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007545722 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/007145 Country of ref document: MX Ref document number: 2590943 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005853909 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005853909 Country of ref document: EP |